FR25C1043I1 - Utilisation de citrate ferrique dans le traitement de patients atteints d'une maladie rénale chronique - Google Patents
Utilisation de citrate ferrique dans le traitement de patients atteints d'une maladie rénale chroniqueInfo
- Publication number
- FR25C1043I1 FR25C1043I1 FR25C1043C FR25C1043C FR25C1043I1 FR 25C1043 I1 FR25C1043 I1 FR 25C1043I1 FR 25C1043 C FR25C1043 C FR 25C1043C FR 25C1043 C FR25C1043 C FR 25C1043C FR 25C1043 I1 FR25C1043 I1 FR 25C1043I1
- Authority
- FR
- France
- Prior art keywords
- patients
- treatment
- kidney disease
- chronic kidney
- ferric citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361800618P | 2013-03-15 | 2013-03-15 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
| EP13807102.2A EP2863906B1 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR25C1043I1 true FR25C1043I1 (fr) | 2026-01-02 |
Family
ID=49769729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR25C1043C Active FR25C1043I1 (fr) | 2012-06-21 | 2025-11-18 | Utilisation de citrate ferrique dans le traitement de patients atteints d'une maladie rénale chronique |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130345303A1 (enExample) |
| EP (3) | EP2863906B1 (enExample) |
| JP (4) | JP2015535209A (enExample) |
| KR (2) | KR20200103855A (enExample) |
| CN (2) | CN113244209A (enExample) |
| AU (2) | AU2013278000A1 (enExample) |
| BR (1) | BR112014032049A2 (enExample) |
| CA (1) | CA2876982A1 (enExample) |
| DK (1) | DK3730136T3 (enExample) |
| EA (1) | EA201590062A1 (enExample) |
| ES (2) | ES2970050T3 (enExample) |
| FR (1) | FR25C1043I1 (enExample) |
| HK (1) | HK1214503A1 (enExample) |
| IL (1) | IL236356A0 (enExample) |
| MX (1) | MX2014015615A (enExample) |
| NO (1) | NO2025048I1 (enExample) |
| PL (1) | PL3730136T3 (enExample) |
| SG (2) | SG10201805177PA (enExample) |
| WO (1) | WO2013192565A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140016438A (ko) | 2009-07-21 | 2014-02-07 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 구연산철 투여형태 |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| RU2728778C2 (ru) | 2013-06-05 | 2020-07-31 | Трисида, Инк. | Протон-связывающие полимеры для перорального введения |
| ES2856261T3 (es) * | 2013-10-01 | 2021-09-27 | Fresenius Medical Care Deutschland Gmbh | Método y aparatos para determinar una pérdida diaria de hierro de un paciente |
| AU2014341975A1 (en) * | 2013-11-04 | 2016-05-19 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| US10172882B2 (en) | 2014-06-22 | 2019-01-08 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| KR102625115B1 (ko) | 2014-12-10 | 2024-01-12 | 트리시다, 인크. | 경구 투여용 양성자-결합 폴리머 |
| JP2018507260A (ja) * | 2015-03-04 | 2018-03-15 | ケリク バイオファーマシューティカルス， インコーポレーテッド | 鉄欠乏性貧血の治療におけるクエン酸第二鉄の使用 |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| IL308673A (en) | 2016-05-06 | 2024-01-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| WO2019059172A1 (ja) | 2017-09-19 | 2019-03-28 | 日本たばこ産業株式会社 | 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用 |
| SG11202003451UA (en) | 2017-11-03 | 2020-05-28 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| CN113613662A (zh) | 2018-10-29 | 2021-11-05 | 法码科思莫斯控股有限公司 | 用羧基麦芽糖铁治疗铁缺乏 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| CN117999069A (zh) | 2021-05-27 | 2024-05-07 | 凯克斯生物制药公司 | 柠檬酸铁的儿科调配物 |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
| WO2025181559A1 (en) * | 2024-02-29 | 2025-09-04 | Sloiron, Inc. | Methods for determining the amount of encapsulated and free iron in a sample |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000067929A (ko) * | 1996-07-19 | 2000-11-25 | 나가타 코이치 | 고인혈증 치료제 |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| KR20080037083A (ko) | 2005-08-18 | 2008-04-29 | 글로보아시아 엘엘씨 | 약학용 등급의 유기 철 화합물, 그 용도 및 이의 제조 방법 |
| KR20180077337A (ko) * | 2006-01-06 | 2018-07-06 | 루이트폴드 파머수티컬스, 인코퍼레이티드 | 철을 투여하기 위한 방법 및 조성물 |
| CN105055446B (zh) * | 2006-01-30 | 2022-06-03 | 宝龄富锦生技股份有限公司 | 逆转、防止、延迟或稳定软组织钙化的方法 |
| KR20140016438A (ko) | 2009-07-21 | 2014-02-07 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 구연산철 투여형태 |
-
2013
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active Ceased
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en not_active Ceased
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active Active
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 HK HK16102352.0A patent/HK1214503A1/zh unknown
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en not_active Withdrawn
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
-
2025
- 2025-11-06 NO NO2025048C patent/NO2025048I1/no unknown
- 2025-11-18 FR FR25C1043C patent/FR25C1043I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1043I1 (fr) | Utilisation de citrate ferrique dans le traitement de patients atteints d'une maladie rénale chronique | |
| EP2968306A4 (en) | ADMINISTRATION OF NICOTINAMIDE MONONUCLEOTIDE IN THE TREATMENT OF DISEASES | |
| EP2903597A4 (en) | USE OF MICROVESICLES IN THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES AND MEDICAL SUDDEN | |
| EP3071280A4 (en) | TREATMENT CATHETER WITH THERAPEUTIC ENERGY SUPPLY | |
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| EP2817621A4 (en) | PROOF OF ANTI-MÜLLER-HORMON IN FULL BLOOD | |
| EP2818483A4 (en) | MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| EP2851429A4 (en) | PROTEIN AND PROTEIN CONJUGATES FOR THE TREATMENT OF DIABETES AND APPLICATIONS THEREOF | |
| EP2912462A4 (en) | BIOMARKERS FOR USE IN THE TREATMENT OF ANEMIA | |
| EP2844279A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS POMPE | |
| EP2867375A4 (en) | USE OF MARKERS IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | |
| EP2800578A4 (en) | SLIT-ROBO-SIGNALING FOR THE DIAGNOSIS AND TREATMENT OF RENAL DISEASES | |
| EP2633865A4 (en) | USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS | |
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| EP2903605A4 (en) | ANGIOTENSIN FOR THE TREATMENT OF BRAIN STATES | |
| EP2914112A4 (en) | TREATMENT OF CANCER WITH POMALIDOMIDE ON A PERSON WITH AFFECTED KIDNEY FUNCTION | |
| IL245317A0 (en) | Ferric citrate for reducing cardiac failure in chronic kidney disease patients | |
| EP2854910A4 (en) | CERAMID MIRRORS IN THE TREATMENT AND PREVENTION OF INFECTIONS | |
| EP2861302A4 (en) | USE OF CCR5 MODULATORS FOR THE TREATMENT OF CANCER | |
| JP2015535291A5 (enExample) | ||
| LT2958624T (lt) | Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas | |
| EP2773340A4 (en) | USE OF NEU1 SIALIDASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3848022C0 (en) | THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION | |
| EP2900259A4 (en) | GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES | |
| EP2938342A4 (en) | INDOL COMPOUNDS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASE AND CANCER |